Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

t and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.  A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 9488233.  The webcast and telephone replay will be available through September 29, 2011.  

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Forward-looking Statements Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different fro
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 31, 2015 Materials in Society ...   June 30 2015   Elsevier , ... and services and publishing home of Materials Today , ... the Materials in Society  Lecture Series . ... 8 th International Conference on Materials for Advanced Technologies ...
(Date:3/31/2015)... 2015  Bayer HealthCare (Bayer) has expanded its ... of Technology (MIT) and Harvard University to include ... this new part of the alliance is to ... new cardiovascular therapies. "We are excited ... to the area of cardiovascular genomics to discover ...
(Date:3/31/2015)... NEW YORK , March 31, 2015 ... a biopharmaceutical company advancing protein biologic therapies and ... Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") ... from the country,s Ministry of Food and Drug ... Institute (KTR) for MuGard, its oncology supportive-care treatment ...
(Date:3/31/2015)... 2015 Today, Cryos International, the world’s ... their U.S. facilities and inventory from New York City ... experience, Cryos’ relocation is a reflection of their increasing ... Orlando was completed during the first weekend of spring, ... place on April 6. The new facility in the ...
Breaking Biology Technology:Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2
... EXTON, Pa., Oct. 2 Othera Pharmaceuticals, ... patient-administered,products for ophthalmology, oncology, and inflammatory disease, ... MD, FACP, as Chief,Scientific Officer effective immediately. ... development, integration and execution of Othera,s research,and ...
... BEIJING and CLAREMONT, Calif., Oct. 2 Kiwa,Bio-Tech Products ... Tianjin Kiwa Feed Limited Liability Company, located in,Wuqing District ... the,month of September. Mr. Wei Li, Chairman and ... in volume of Kiwa,s bio-feed products to approximately 7,550 ...
... Posters at Medical Conference in San Diego, ... October 4 ... - 7, 2007 -, CHICAGO, Oct. ... the,discovery, development and commercialization of novel drugs in the,therapeutic areas of infection, cancer and inflammation, ...
Cached Biology Technology:Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 2Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 3Kiwa Bio-Tech Ships 2,700 Tons of Bio-feed in One Month 2Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 2Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 3
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
(Date:3/10/2015)... , March 10, 2015   Tute Genomics ... has been selected by next-generation sequencing company PrimBio ... whole exome and targeted gene panel interpretation. ... has adopted the most current technologies to support the ... research. The company offers two types of exome sequencing ...
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... FirstMark, the diagnostic division of GenWay Biotech, Inc., is ... and presenting at the San Diego Academy of Family ... 22-24. FirstMark will showcase the groundbreaking research and data ... first and only multiple biomarker blood test on the ...
... life, but for those species that do, wildlife biologists have ... relationships: greater longevity and breeding success, according to a study ... published in Behavioral Ecology . The study,s authors ... lose their mate, their chances for survival are greatly diminished. ...
... ointment, light on, light off that,s how easy it ... the majority of patients suffer severe pain during the so-termed ... can be so painful has now been uncovered by researchers ... signalling molecules secreted by the cancer cells. "The results may ...
Cached Biology News:FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium 2Black brant geese show lifetime relationship good for goose and gander 2Double the pain: RUB biologists find the cause of pain in the treatment of fair skin cancer 2
Request Info...
... Monoclonal Mouse Antibody to Cytokeratin 5 / ... a high molecular weight, basic type of ... the superficial cell layers of stratified epithelia ... and in mesothelial cells and mesothelioma. Cytokeratin ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Biology Products: